Christopher Gibson, Ph.D., is our co-founder, Chief Executive Officer since the company’s founding in November 2013. Dr. Gibson was also Chairman of our Board from the company’s founding until he asked, with the support of the rest of the Board, for Dr. R. Martin Chavez to accept a position of Chairman in January 2021.
Previously, Dr. Gibson was an M.D./Ph.D. student at the University of Utah. After obtaining his Ph.D., he withdrew from medical school to found Recursion. He has undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) Rice University. He has served as a Founding Chairman of the Board of BioHive (the Utah life science collective and branding effort, composed of therapeutics, diagnostics, medical device and health IT companies, along with the companies that support them and the public sector) since November 2020. He also serves as a Board member of BioUtah (the Utah life science industry association) since January 2019, Board member of the Recursion Foundation (our not-for-profit entity seeking to promote corporate social responsibility) since November 2019, through which he is on the Board of Altitude Lab (an incubator/accelerator focused on creating the next generation of diverse biotech founder in Utah) since July 2020.
Dr. Gibson has also served on the Cures Acceleration Network Review Board since September 2020. Dr. Gibson is co-author of more than a dozen peer-reviewed studies in a variety of journals including Nature, Nature Protocols, Circulation, the Journal of Clinical Investigation, Molecular Pharmaceutics, PloS One, and Diabetes. Our Board believes Dr. Gibson is qualified to serve on our Board because of his scientific and technical background and his knowledge and perspective of the Company.
What is Christopher Gibson's net worth?
The estimated net worth of Christopher Gibson is at least $5.78 million as of October 2nd, 2024. Dr. Gibson owns 762,656 shares of Recursion Pharmaceuticals stock worth more than $5,780,932 as of December 3rd. This net worth estimate does not reflect any other investments that Dr. Gibson may own. Additionally, Dr. Gibson receives an annual salary of $806,720.00 as CEO at Recursion Pharmaceuticals. Learn More about Christopher Gibson's net worth.
How old is Christopher Gibson?
What is Christopher Gibson's salary?
How do I contact Christopher Gibson?
Has Christopher Gibson been buying or selling shares of Recursion Pharmaceuticals?
Within the last three months, Christopher Gibson has sold $123,200.00 in Recursion Pharmaceuticals stock. Most recently, Christopher Gibson sold 20,000 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a transaction totalling $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company's stock, valued at $4,697,960.96. Learn More on Christopher Gibson's trading history.
Who are Recursion Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Recursion Pharmaceuticals?
In the last year, insiders at the sold shares 60 times. They sold a total of 1,139,854 shares worth more than $10,019,385.72. The most recent insider tranaction occured on November, 13th when CFO Michael Secora sold 15,000 shares worth more than $114,900.00. Insiders at Recursion Pharmaceuticals own 15.8% of the company.
Learn More about insider trades at Recursion Pharmaceuticals. Information on this page was last updated on 11/13/2024.
